Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2007 Jan;11(1):12-5.

Chapter 4: childhood contact screening and management

  • PMID: 17217124
Practice Guideline

Chapter 4: childhood contact screening and management

World Health Organization Stop TB Partnership Childhood TB Subgroup. Int J Tuberc Lung Dis. 2007 Jan.

Abstract

Young children living in close contact with a case of smear-positive pulmonary TB (PTB) are at particular risk of Mycobacterium tuberculosis infection and TB disease. Screening of the household contacts of an infectious source case is therefore recommended to identify children with TB and enable their prompt treatment, and to provide children who do not have TB with isoniazid preventive treatment. Isoniazid preventive treatment (IPT) is particularly beneficial in the case of children who are infected with the human immunodeficiency virus (HIV). A breastfeeding infant has a particularly high risk of infection from a mother with smear-positive pulmonary TB, and a high risk of developing TB. The infant should receive 6 months of IPT, followed by BCG vaccination. Breastfeeding can be safely continued in children during this period. The organisation of a system for comprehensive child contact screening depends on collaboration between the National TB Programme (NTP) and all child health providers. Close contacts of multidrug-resistant (MDR) TB patients should receive careful clinical followup for at least 2 years. If active disease develops, prompt initiation of treatment with a regimen designed to treat MDR-TB is recommended. On the basis of the currently available evidence, the World Health Organization does not recommend second-line drugs for chemoprophylaxis in MDR-TB contacts.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources